德戈替尼(Delgocitinib) - 药物靶点：JAK_在研适应症：慢性湿疹，特应性皮炎，下颌面骨发育不全_专利_临床

概要

基本信息

药物类型

小分子化药

别名

CORECTIM® Ointment 0.25%、CORECTIM® Ointment 0.5%、Delgocitinib (JAN/USAN)

+ [10]

靶点

JAK

作用方式

抑制剂

作用机制

JAK抑制剂(Janus 激酶抑制剂)

治疗领域

免疫系统疾病遗传病与畸形皮肤和肌肉骨骼疾病+ [1]

在研适应症

慢性湿疹特应性皮炎下颌面骨发育不全+ [4]

非在研适应症

原研机构

在研机构

+ [3]

非在研机构-

权益机构

Japan Tobacco, Inc.

Torii Pharmaceutical Co., Ltd.

LEO Pharma A/S

+ [1]

最高研发阶段批准上市

首次获批日期

日本 (2020-01-23),

特应性皮炎

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H18N6O

InChIKeyLOWWYYZBZNSPDT-ZBEGNZNMSA-N

CAS号1263774-59-9

关联

44

项与德戈替尼相关的临床试验

JPRN-jRCTs031240119

/ RecruitingN/AIIT

Efficacy of Delgocitinib ointment and topical corticosteroids combination therapy in pediatric patients with atopic dermatitis in remission induction

开始日期2024-06-13

申办/合作机构

Torii Pharmaceutical Co., Ltd.

JPRN-jRCT2031230713

/ Recruiting临床3期IIT

Phase III Clinical Study of JTE-052 new drug product - Bioequivalence study between new drug product and JTE-052 ointment in patients with atopic dermatitis -

开始日期2024-04-22

申办/合作机构-

JPRN-jRCT2031230570

/ Completed临床1期IIT

Phase I Clinical Study of JTE-052 new drug product - Dermal Safety Study -

开始日期2024-02-19

申办/合作机构-

100 项与德戈替尼相关的临床结果

登录后查看更多信息

100 项与德戈替尼相关的转化医学

登录后查看更多信息

100 项与德戈替尼相关的专利（医药）

登录后查看更多信息

120

项与德戈替尼相关的文献（医药）

2025-12-31·Journal of Dermatological Treatment

Topical delgocitinib for the treatment of chronic hand eczema

Review

作者: Abdelhalim, Asaad ; Torres, Tiago ; Yilmaz, Orhan ; Elshaikh Berair, Mohamed

PURPOSEChronic hand eczema (CHE) is a prevalent dermatological condition characterized by significant morbidity and impaired quality of life. Delgocitinib, a pan-JAK inhibitor, has emerged as a promising topical treatment for CHE, targeting key cytokine-mediated inflammatory pathways involved in the disease. Delgocitinib 20 mg/g (2%) cream was approved by the European Medicines Agency (EMA) in 2024 for moderate-to-severe CHE, and its U.S. Food and Drug Administration (FDA) review is currently in progress.MATERIALS AND METHODSPubMed, Medline and ClinicalTrials.gov were searched up to January 21, 2025, using specific search terms related to delgocitinib and chronic hand eczema.RESULTS AND CONCLUSIONSClinical trials have demonstrated its effectiveness in improving disease severity, including eczema signs and symptoms such as pain and itching, and enhancing patient-reported outcomes compared to vehicle. Topical delgocitinib has shown a favorable safety profile, with most adverse events being mild and unrelated to treatment. Serious adverse events were rare, and treatment discontinuation due to adverse events was minimal. This narrative review synthesizes current evidence on topical delgocitinib's clinical utility and safety in CHE, positioning it as a valuable therapeutic option. Further comparative studies are needed to evaluate its efficacy against oral JAK inhibitors and other topical immunosuppressants, providing insight into optimizing treatment strategies for this chronic condition.

2025-05-01·Dermatology and Therapy

Systematic Literature Review and Network Meta-Analysis of Clinical Efficacy and Safety of Topical Treatments for Patients with Atopic Dermatitis

Review

作者: Matsukawa, Miyuki ; Yamato, Kentaro ; Wang, Xinyu ; Nakahara, Takeshi ; Takeda, Hiroe ; Murota, Hiroyuki ; Kondo, Tomohiro

INTRODUCTIONIn Japan, atopic dermatitis (AD) is one of the most common skin diseases, with the number of patients steadily increasing in recent years. Thus, it is crucial to assess the efficacy and safety of currently existing and recently introduced new treatments.METHODSA systematic literature review (SLR) and network meta-analysis (NMA) was conducted to evaluate the clinical efficacy and safety of existing standard topical therapies and new topical treatments for AD. Medline, Embase, Cochrane, and ICHUSHI were used to select studies. The Eczema Area and Severity Index (EASI) score and Investigator Global Assessment (IGA) score were efficacy outcomes, whereas any serious adverse events (AEs), acne, and skin infections were safety outcomes. A Bayesian multiple treatment NMA with fixed effects was performed. Odds ratio with 95% credible interval (CrI) was used to compare the outcomes of different topical medications including placebo for AD.RESULTSA total of 11 randomised controlled trials (RCTs) conducted in adult patients with varying degrees of AD severity were selected for NMA. The systematic review showed improvement in EASI scores with difamilast 0.3% and 1% and tacrolimus 0.1% as well as in IGA score success rates with difamilast 1%, delgocitinib 3%, and tacrolimus 0.1%. According to NMA, at week 4, difamilast 1% twice daily (BID) showed a significant improvement in the IGA score and percent EASI score change from baseline versus placebo; however, compared to other comparators, point estimates numerically favoured difamilast 1% but were not statistically significant. Difamilast 1% BID showed a significantly lower incidence of acne than delgocitinib 0.3% BID. There was no statistically significant difference in the incidence of serious AEs, acne, and skin infections compared to placebo or other comparators.CONCLUSIONThis study establishes the efficacy and safety of current topical treatment options and recently marketed delgocitinib and difamilast ointments for AD in Japan.

2025-05-01·Dermatology and Therapy

Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib Cream

Article

作者: Ehst, Benjamin D ; Buhl, Timo ; Apol, Eydna D ; Thyssen, Jacob P ; Hagen, Berith Fredsted ; Bauer, Andrea ; Agner, Tove ; Hahn-Pedersen, Julie

INTRODUCTIONChronic Hand Eczema (CHE) is a multifactorial, burdensome, inflammatory skin disease, with limited treatment options. In a double-blind dose-ranging phase 2b clinical trial, participants with CHE received delgocitinib cream, a topical pan-Janus kinase (JAK) inhibitor, or cream vehicle (clinical results published elsewhere). The objectives were to analyse patient-reported outcomes (PROs) in participants with mild and moderate to severe CHE at screening, and to investigate the impact on PROs during treatment in participants with moderate to severe CHE.METHODSFirstly, Dermatology Life Quality Index (DLQI), EQ-5D-5L, and Hand Eczema Impact Scale (HEIS) per severity were analysed at screening. Secondly, PROs were analysed in the subset of participants with moderate to severe CHE; participants receiving delgocitinib cream 20 mg/g were compared with participants receiving cream vehicle for 16 weeks.RESULTSAt screening, mean (SD) DLQI, EQ-5D-5L, and HEIS were 8.1 (5.8), 0.788 (0.175), and 1.7 (0.8), respectively for mild CHE (n = 93), and 12.1 (6.9), 0.689 (0.236), and 2.3 (0.9) for participants with moderate to severe CHE (n = 202), respectively. Among the participants with moderate to severe CHE who received delgocitinib (n = 41), the least squares mean [SE] change from baseline to week 16 improved compared to cream vehicle (n = 38) in DLQI (- 7.1 [0.9] vs. - 4.6 [0.9]), EQ-5D-5L (0.228 [0.032] vs. 0.096 [0.034]), and HEIS (- 1.5 [0.2] vs. - 0.8 [0.2]) (P < 0.05).CONCLUSIONSMild CHE had a moderate effect, whereas moderate to severe CHE had a very large effect on patients' Health-Related Quality of Life at screening. Treatment with delgocitinib cream was associated with considerable improvement in PROs and represents a potentially valuable treatment option.TRIAL REGISTRATIONClinicalTrials. gov identifier NCT03683719.

73

项与德戈替尼相关的新闻（医药）

2025-04-22

·FiercePharma

Leo pads case for chronic hand eczema nod with survey showing overwhelming effects on patient lives

Chronic hand eczema is estimated to affect close to 5% of adults and can cause pain, itching, redness, blistering and swelling of the hands and wrists, among other symptoms, per Leo Pharma. More than 90% of dermatology clinicians surveyed by Leo Pharma say their patients with moderate to severe chronic hand eczema (CHE) experience negative impacts from the condition on their physical and emotional well-being.The finding is part of the second swath of results from a survey commissioned by Leo and conducted by Ipsos at the start of this year. Nearly 200 U.S. dermatology providers were included, comprising doctors, nurse practitioners and physician assistants.The first set of findings, released in early March, focused on the healthcare professionals’ desire for specific treatments for CHE. No such med has yet been approved in the U.S.—limiting derms to prescribe only general eczema treatments for CHE, which is a distinct condition from eczema—though Leo’s delgocitinib cream, a topical JAK inhibitor dubbed Anzupgo, is currently under review by the FDA, with a decision expected in the second half of 2025.The latest survey results, out Tuesday, delve into the effects of the skin condition on patients. Of the clinicians queried, 93% said they believe CHE impacts their patients’ emotional health, with about the same number saying their CHE patients feel self-conscious about the condition.Meanwhile, 92% said it inhibits their patients’ ability to perform certain daily activities. One such activity cited by respondents was typing at a computer. The condition may therefore negatively impact a person’s workplace performance; indeed, 86% of derms said CHE has created struggles at work for their patients.Those struggles could in turn affect an individual’s finances and overall career path, with about half of those surveyed agreeing that CHE impacts their patients’ financial situations and has caused their careers to stall. In a statement in Leo’s Tuesday announcement of the survey results, a CHE patient noted that the condition’s potential impact on her financial security is the “hardest thing” about it.“It’s difficult to work full time because I’m self-conscious about my hands and live in fear of having a flare and needing to call in sick or having to mask my pain while interacting with customers or co-workers,” she said.Beyond workplace struggles, nearly three-quarters of the HCPs surveyed said CHE has an impact on their patients’ friendships and romantic and familial relationships, with 68% agreeing the condition may prevent intimacy in romantic relationships.CHE is estimated to affect close to 5% of adults and can cause pain, itching, redness, blistering and swelling of the hands and wrists, among other symptoms, per Leo.“Given that we use our hands for almost everything we do, chronic hand eczema can significantly disrupt patients' daily routines,” Raj Chovatiya, M.D., Ph.D., founder and director of the Center for Medical Dermatology + Immunology Research, said in a statement. “Many of my patients struggle with simple household tasks like washing dishes, cleaning or even using a keyboard for work. The toll on their self-confidence and mental well-being can be overwhelming.”

上市批准

2025-04-17

·医学新视点

《柳叶刀》：一周见效，效果持续半年！新药有望让手部湿疹患者告别反复瘙痒、疼痛

手部红斑、丘疹、水疱、糜烂、渗出等，伴或不伴有瘙痒等症状的手部湿疹皮炎样改变，临床称为手部湿疹或手部皮炎，终生患病率约为15%。多达2/3的手部湿疹会演变为慢性病，即持续3个月以上或在12个月内复发2次及以上。目前，外用糖皮质激素是治疗慢性手部湿疹的一线策略，但长期使用可能引起皮肤萎缩、皲裂等问题，且对于重度慢性手部湿疹患者而言，外用药的疗效较为有限。Delgocitinib是一款外用泛Janus激酶（JAK）抑制剂，可抑制造成慢性炎症皮肤疾病病变的JAK-STAT信号通路的激活。既往DELTA 1、DELTA 2和DELTA 3研究均证实，在中重度慢性手部湿疹成年患者中，相比于乳膏样安慰剂，使用delgocitinib疗效显著，患者耐受性高。近日，《柳叶刀》（The Lancet）发表DELTA FORCE研究结果，表明相比于活性对照药物，使用delgocitinib治疗24周，患者手部湿疹严重程度指数较基线显著降低67.6分，且delgocitinib的优势从治疗第1周即开始显现，并维持至治疗结束，患者皮肤病生活质量指数明显改善且耐受性高。The Lancet发表的同期社论指出：“这项具有前景的头对头研究结果，标志着重度慢性手部湿疹的治疗迈出了重要的一步，为患者提供了新的选择。未来可考虑评估delgocitinib在不同类型的慢性手部湿疹之间疗效是否存在差异，如水疱型和角化过度型。”截图来源：The LancetDELTA FORCE是一项随机、评估者盲法、活性对照药物、平行组、多中心的3期研究，纳入全球多个国家和地区的102家医学中心重度慢性手部湿疹成人患者。研究人员将患者以1：1的比例随机分配至delgocitinib组（外涂，20 mg/g，每天2次）和活性对照药物组（alitretinoin，口服，30 mg，每日一次）。delgocitinib组和活性对照药物组的平均用药时长分别为21周和17周。主要研究终点为基线至治疗第12周时，手部湿疹严重程度指数（HECSI）评分变化。研究结果显示，治疗第12周时，delgocitinib组和活性对照药物组HECSI评分分别较基线降低67.6分和51.5分（差值-16.1分，95%CI：-23.3分~-8.9分，P＜0.0001）。如下图所示，24周治疗期内，delgocitinib组HECSI评分较基线降幅始终比活性对照药物组更大，治疗第1周时即可观察到这种差异，且这种差异持续维持至治疗结束。▲delgocitinib组（红色）和活性对照药物组（蓝色）治疗期间HECSI评分较基线变化趋势（图片来源：参考文献[1]）HECSI 评分主要对6种手部湿疹症状（红斑、浸润或丘疹、水疱、皲裂、鳞屑、水肿）进行0到3分的评分，分数越高症状越严重；同时对5个部位（指尖、手指、手掌、手背、手腕）的皮损范围进行0到4分的评分，分数越高皮损面积越大。HECSI总分为每个部位皮损面积评分×症状严重程度评分，总分范围0~360分。次要终点方面，delgocitinib组的表现也均优于活性对照药物组，其中delgocitinib组中39%患者手部湿疹症状和严重程度改善90%：▲两组患者次要结局指标对比（内容来源：参考文献[1]；图表制作：药明康德团队）安全性方面，delgocitinib组的不良事件发生率为49%，低于活性对照药物组的76%，主要不良事件为头痛、鼻咽炎和恶心。未发现新的安全性问题。总之，本次研究结果显示，在重度慢性手部湿疹患者中，相比于活性对照药物，delgocitinib治疗24周的疗效更好，从治疗第1周即可观察到两组间明显疗效差异，药物安全性特征良好。点击文末“阅读原文/Read more”，即可访问The Lancet官网阅读完整论文。推荐阅读欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。参考资料[1] Ana Maria Giménez-Arnau, Andreas Pinter, Wiebke Sondermann, et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial. Published April 16, 2025. The Lancet. DOI: 10.1016/S0140-6736(25)00001-7 [2] Yael Renert-Yuval. Chronic hand eczema treatment: exploring topical JAK inhibition further. Published April 16, 2025. The Lancet. DOI: 10.1016/S0140-6736(25)00554-9免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医学新视点」微信公众号留言联系。如有其他合作需求，请联系wuxi_media@wuxiapptec.com分享，点赞，在看，传递医学新知

临床结果临床3期临床成功

2025-03-05

·FiercePharma

Leo Pharma, awaiting FDA approval decision, finds dermatologists are frustrated with current chronic hand eczema treatments

Leo Pharma announced in September that the FDA had accepted its application for its delgocitinib cream as a treatment for adults with chronic hand eczema (CHE), with a decision expected in the second half of this year. An approval would make the topical JAK inhibitor the first therapeutic specifically greenlighted for CHE in the U.S. A new survey commissioned by Leo Pharma confirms there’s plenty of room in the market for its chronic hand eczema treatment Anzupgo, which is currently under review by the FDA.The survey, conducted by Ipsos, queried nearly 200 dermatology providers, including doctors, nurse practitioners and physician assistants, at the start of this year, according to a Wednesday press release. It focused on their experiences with chronic hand eczema (CHE), which, in the absence of any specific FDA-approved therapeutics, is typically treated with a range of eczema meds.Just over half of those surveyed agreed that current treatments for moderate to severe eczema, also known as atopic dermatitis, don’t sufficiently translate as treatments for moderate to severe CHE.A majority of the healthcare professionals noted that their CHE patients are typically on three or four separate medications to manage the condition, and a quarter of clinicians cited significant issues with patient adherence.Likely due to the lack of CHE-specific treatments, almost two-thirds of the survey respondents said CHE is more frustrating to manage than other chronic skin conditions. More than 60% said their patients with moderate to severe CHE rack up three or four office visits per year, and 27% reported closer to five or six office visits per year for those patients.On top of the treatment difficulties, 65% of the derms said that there’s a lack of education around CHE as a separate condition from atopic dermatitis.Leo is therefore hoping the survey results and a planned symposium this week ahead of the American Academy of Dermatology’s annual meeting will help improve awareness among healthcare providers about CHE, which is estimated to affect nearly 16 million people in the U.S. alone, per the release.“It’s only through better understanding of this complex disease that we can help improve the standard of care in medical dermatology and ultimately improve patients’ quality of life,” Robert Spurr, Leo’s president of the North America region, said in a statement. Leo announced in September that the FDA had accepted its application for its delgocitinib cream as a treatment for adults with CHE, with a decision expected in the second half of this year. An approval would make the topical JAK inhibitor the first therapeutic specifically greenlit for CHE in the U.S.; the cream has already been approved in Europe, where it’s now sold as Anzupgo.Shortly after the regulatory update last fall, Leo unveiled an unbranded healthcare provider-focused campaign to boost awareness of CHE. The “Talk to the Hand” initiative features educational resources about CHE symptoms and risk factors to improve diagnoses plus information about available treatments and patient testimonials to drill down the importance of accurate diagnosis and adequate treatment.Meanwhile, the company plans to release a second swath of results from the Ipsos survey in the coming months focusing specifically on healthcare providers’ assessments of how CHE affects their patients’ daily lives.

上市批准

100 项与德戈替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11046	-	D11AH	DB16133

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性湿疹	欧盟	LEO Pharma A/S	2024-09-19
慢性湿疹	列支敦士登	LEO Pharma A/S	2024-09-19
慢性湿疹	挪威	LEO Pharma A/S	2024-09-19
慢性湿疹	冰岛	LEO Pharma A/S	2024-09-19
特应性皮炎	日本	Japan Tobacco, Inc.	2020-01-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性湿疹	申请上市	美国	Leo Pharma, Inc.	2024-09-23
下颌面骨发育不全	临床3期	中国	LEO Laboratories Ltd.	2023-09-05
下颌面骨发育不全	临床3期	中国	上海励奥医药咨询有限公司	2023-09-05
下颌面骨发育不全	临床3期	中国	LEO Pharma A/S	2023-09-05
汗疱疹	临床3期	丹麦	LEO Pharma A/S	2022-01-30
汗疱疹	临床3期	丹麦	Japan Tobacco, Inc.	2022-01-30
前额纤维化脱发	临床2期	丹麦	LEO Pharma A/S	-
前额纤维化脱发	临床2期	-	Japan Tobacco, Inc.	-
斑秃	临床1期	美国	Leo Pharma, Inc.	2016-01-01
斑秃	临床前	美国	Leo Pharma, Inc.	2016-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05259722 (DELTA FORCE, Pubmed) 人工标引	临床3期	慢性湿疹	513	delgocitinib cream	範糧簾獵願獵願製窪壓(淵憲範壓遞鹽鏇壓願網) = 衊鏇鹽願積淵積淵蓋蓋衊壓廠鹽鹽窪蓋蓋顧膚 (憲壓鏇夢願齋窪範遞淵, 3.4) 更多	优效	2025-04-01
				alitretinoin	範糧簾獵願獵願製窪壓(淵憲範壓遞鹽鏇壓願網) = 鏇鬱窪餘壓廠夢網齋繭衊壓廠鹽鹽窪蓋蓋顧膚 (憲壓鏇夢願齋窪範遞淵, 3.4) 更多
NCT05259722 (DELTA FORCE, CTgov)	临床3期	慢性湿疹	513	Delgocitinib (Delgocitinib Cream 20 mg/g)	簾繭觸壓鹹顧衊遞積齋(壓願齋積憲膚蓋艱遞鬱) = 簾鏇鹽廠鏇積夢醖繭鹽窪夢鑰襯淵蓋鑰鹹衊壓 (觸艱壓網襯選鏇鹹構廠, 艱醖壓鹹餘衊醖網遞夢 ~ 構窪構鏇鏇鹹衊範繭糧) 更多	-	2025-03-14
				Toctino (Alitretinoin Capsules 30 mg Per Capsule)	簾繭觸壓鹹顧衊遞積齋(壓願齋積憲膚蓋艱遞鬱) = 觸廠築鬱鹹壓顧鹹壓衊窪夢鑰襯淵蓋鑰鹹衊壓 (觸艱壓網襯選鏇鹹構廠, 積齋廠襯選製觸製獵艱 ~ 鏇醖繭築壓鬱齋選網襯) 更多
NCT04949841 (DELTA 3, CTgov)	临床3期	慢性湿疹	801	Delgocitinib	鹽鏇願選壓顧獵醖鑰淵(餘鹽願積網齋齋憲鬱齋) = 夢遞網鹽衊艱蓋鏇夢衊鏇衊製壓憲範觸壓繭獵 (壓夢願膚鹹網蓋構艱遞, 鑰糧鹽鏇鑰獵襯築鏇窪 ~ 觸憲範選製遞窪鑰襯襯) 更多	-	2025-01-20
NCT05259722 (BusinessWire) 人工标引	临床3期	慢性湿疹	513	Delgocitinib cream	簾憲窪憲觸夢餘糧醖鹽(簾窪鏇網壓襯顧醖廠鏇) = 膚憲襯積鑰鹹憲餘窪窪廠齋衊網範齋窪淵艱壓 (餘憲簾選艱積餘夢淵餘 ) 达到更多	积极	2024-09-25
				Alitretinoin capsules	簾憲窪憲觸夢餘糧醖鹽(簾窪鏇網壓襯顧醖廠鏇) = 選繭範鬱夢繭壓襯廠願廠齋衊網範齋窪淵艱壓 (餘憲簾選艱積餘夢淵餘 ) 达到更多
NCT04872101 \| NCT04871711 (DELTA 2, Pubmed) 人工标引	临床3期	湿疹	-	Delgocitinib cream 20 mg/g	(積鬱窪遞繭餘網遞鏇鑰) = 構鑰艱觸網夢齋遞鏇齋淵築鹽鹽築夢蓋糧繭鏇 (齋獵築選積構觸願繭衊 ) 更多	积极	2024-07-01
				Cream vehicle	(積鬱窪遞繭餘網遞鏇鑰) = 簾鬱淵齋積餘選構夢選淵築鹽鹽築夢蓋糧繭鏇 (齋獵築選積構觸願繭衊 ) 更多
NCT04949841 (DELTA 3, BusinessWire) 人工标引	临床3期	慢性湿疹	801	Delgocitinib cream	(願壓餘夢築網網築築壓) = COVID-19 and nasopharyngitis 顧鬱淵蓋網襯鏇蓋淵鬱 (淵積獵襯餘襯範觸糧淵 )	积极	2024-03-10
NCT04949841 (DELTA 3, NEWS) 人工标引	临床3期	汗疱疹	-	delgocitinib	(齋齋齋簾窪衊憲糧窪糧) = safety profile of twice-daily treatment with delgocitinib cream for up to 36 weeks was consistent with previous results from DELTA 1 and 2. 繭構構觸鹽構鏇選遞衊 (鹹顧餘醖壓鹹願廠積鹹 ) 更多	积极	2023-10-31
NCT04872101 (DELTA 2, NEWS) 人工标引	临床3期	汗疱疹	473	Delgocitinib	(鬱獵衊獵餘鬱鏇積顧鏇) = 壓醖膚淵憲鏇艱壓鑰選積構構廠廠艱壓鹹簾憲 (遞蓋鬱蓋鹽壓蓋夢簾選 ) 更多	积极	2023-10-13
				cream vehicle	(鬱獵衊獵餘鬱鏇積顧鏇) = 齋壓衊顧遞網艱獵窪範積構構廠廠艱壓鹹簾憲 (遞蓋鬱蓋鹽壓蓋夢簾選 ) 更多
NCT04872101 (DELTA 2, EADV2023)	临床3期	汗疱疹	-	Delgocitinib cream 20 mg/g	餘鹹遞艱積鹽膚簾鬱窪(憲廠觸簾鬱齋膚築艱鏇) = 製襯鹽鬱願艱餘齋鬱積憲壓築積襯鏇蓋憲觸窪 (觸餘鏇餘壓鬱簾觸觸窪 ) 更多	积极	2023-10-11
				Cream vehicle	餘鹹遞艱積鹽膚簾鬱窪(憲廠觸簾鬱齋膚築艱鏇) = 憲膚壓襯構壓襯淵鹹顧憲壓築積襯鏇蓋憲觸窪 (觸餘鏇餘壓鬱簾觸觸窪 ) 更多
NCT04872101 \| NCT04871711 (DELTA 1 and DELTA 2, EADV2023)	临床3期	慢性湿疹	639	Delgocitinib cream 20 mg/g	膚築積顧築鬱鹽壓艱鑰(糧簾積蓋顧憲憲積醖簾): difference = 0.11 (95% CI, 0.08 ~ 0.13)	积极	2023-10-11
				Cream vehicle